Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Core Insights - ImmuneOnco has initiated a Phase 1b/2 clinical trial for IMM2510/SYN-2510 in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China, with the first patient dosed [1][2] - Initial clinical data from this trial is expected to be presented in the second half of 2025 [1][2] - Instil Bio plans to initiate a similar first-line advanced NSCLC clinical trial in the U.S. in the second half of 2025, pending regulatory approvals [3] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies, with SYN-2510 as its lead asset, a PD-L1xVEGF bispecific antibody targeting multiple solid tumor cancers [5] - SYN-2510/IMM2510 is differentiated by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A, and enhances antibody-dependent cellular cytotoxicity (ADCC) [4]